Apellis Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
APLS Apellis Pharmaceuticals Inc
RVVTF Revive Therapeutics Ltd
AMD Advanced Micro Devices Inc
IDAI T Stamp Inc
VZ Verizon Communications Inc
CETX Cemtrex Inc
RNXT RenovoRx Inc
ARTW Art's Way Manufacturing Co Inc
ARIZU Arisz Acquisition Corp

Health Care : Biotechnology | Mid Cap Growth
Company profile

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. Its SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). The Company’s EMPAVELI (pegcetacoplan) is the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) is the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has an approval for the treatment of PNH in Saudi Arabia, Australia, and the United Kingdom. Systemic pegcetacoplan markets under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union and United Kingdom.

Day's Change
-0.335 (-0.51%)
B/A Size
Day's High
Day's Low

Today's volume of 69,340 shares is on pace to be much lighter than APLS's 10-day average volume of 1,814,124 shares.

  • Prev Close
  • Today's Open
  • Day's Range
  • Avg Vol (10-day)
  • Last (time)
    10:19a ET 03/28/23
  • Last (size)
  • 52-Wk Range
    33.32 - 70.76
  • (05/11/22 - 02/23/23)
  • 60.8%
  • Market Cap
  • Shares Outstanding
  • -6.13
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 1.2
  • 87.83
  • (% of float 02/28/23)

Latest News

March 06, 2023
4:05 pm ET
Globe Newswire
March 01, 2023
7:00 am ET
Globe Newswire
February 27, 2023
5:19 pm ET
Globe Newswire
February 22, 2023
9:48 pm ET
Globe Newswire
9:31 am ET
PR Newswire
7:22 am ET
Globe Newswire
February 21, 2023
5:55 pm ET
4:14 pm ET
Globe Newswire
8:39 am ET
PR Newswire
February 17, 2023
4:06 pm ET
Globe Newswire
February 13, 2023
4:05 pm ET
Globe Newswire
January 13, 2023
7:22 am ET
January 06, 2023
4:05 pm ET
Globe Newswire
January 05, 2023
7:00 am ET
Globe Newswire
January 03, 2023
7:00 am ET
Globe Newswire
November 18, 2022
8:50 am ET
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.